HighTower Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

HighTower Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-20,000	Closed	-$2K	–	2524
2020 Q1	$2K	Buy	20,000 +4,800	+32%	+$35.6K	﹤0.01%	2183
2019 Q4	$13K	Buy	15,200 +11,200	+280%	+$103K	﹤0.01%	2190
2019 Q3	$3K	Buy	+4,000	New	+$44.9K	﹤0.01%	2352
2019 Q1	–	Sell	-2,000	Closed	-$13K	–	2413
2018 Q4	$13K	Hold	2,000	–	–	﹤0.01%	2115
2018 Q3	$13K	Buy	+2,000	New	+$30.4K	﹤0.01%	2193

Other funds holding SGMO

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

AIM

Axiom Investment Management New York $150M AUM

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

HIG

Heritage Investment Group Pompano Beach, Florida $744M AUM 20.51% 1-Year Est. Return

HighTower Advisors's SGMO Position: Q2 2026 in Review

HighTower Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2026, closing a stake of 706,481 shares — an estimated $174K sold.

HighTower Advisors first reported a position in SGMO in Q4 2014 and held it in 45 quarters. The position peaked at $7.14M in Q4 2021. 6 funds tracked by Wall St. Rank hold SGMO as of Q2 2026.

HighTower Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2026 after selling out during the quarter.
HighTower Advisors sold 706,481 SANGAMO THERAPEUTICS INC shares in Q2 2026, an estimated $174K.
HighTower Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and held it in 45 quarters.
HighTower Advisors's SANGAMO THERAPEUTICS INC position peaked at $7.14M in Q4 2021.
6 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.